Glaxo hails 'important milestone' for HIV drug

Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.

ViiV Healthcare, a global HIV firm established by Glaxo and Pfizer, and Shionogi & Co announced this morning that the SPRING-2 (ING113086) - the Phase III study of the investigational integrase inhibitor dolutegravir in treatment-nave adults with HIV-1 - met its primary objective, showing non-inferiority of dolutegravir to raltegravir.

"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future," sid ViiV's Chief Medica Officer John Pottage.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

"These are the first large-scale safety and efficacy data in nave patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," he said.

During a period of 48 weeks, 88% of study participants on the one-daily drug were "virologcially supressed" compared with 85% of participants on raltegravir (twice daily).

Shionogi & Co's Chief Executive Officer, Tsutae Nagata, said that the findings mark an "important milestone" for dolutegravir and the Shionogi-ViiV joint venture.

BC